Loading...
•
Jun 30, 2025
Fulgent Q2 2025 Earnings Report
Fulgent reported its second quarter 2025 financial results, with total revenue of $81.8 million and a GAAP loss of $19.0 million.
Key Takeaways
Fulgent Genetics reported a total revenue of $81.8 million for the second quarter of 2025, with core revenue growing 16% year-over-year to $81.7 million. The company experienced a GAAP net loss of $19.0 million, or ($0.62) per share, which included a one-time charge. Non-GAAP income was $2.1 million, or $0.07 per share. The company ended the quarter with $777.5 million in cash, cash equivalents, restricted cash, and investments in marketable securities.
Total revenue for Q2 2025 was $81.8 million.
Core Revenue increased by 16% year-over-year, reaching $81.7 million.
GAAP net loss was $19.0 million, or ($0.62) per share, impacted by a one-time charge.
Non-GAAP income stood at $2.1 million, or $0.07 per share.
Revenue by Segment
Forward Guidance
For the full year 2025, Fulgent expects core revenue of approximately $320.0 million, a GAAP loss of approximately ($2.10) per share, and a non-GAAP loss of approximately ($0.35) per share. Cash, cash equivalents, restricted cash, and investments in marketable securities are expected to be approximately $770.0 million as of December 31, 2025.
Positive Outlook
- Raising full year 2025 Core Revenue Guidance to $320 million.
- Anticipated cash, cash equivalents, restricted cash, and investments in marketable securities of approximately $770.0 million by year-end 2025.
- Good progress in growing revenue for the Laboratory Services business.
- Advancement in clinical trials for the Therapeutic Development business.
- Positive momentum and hard work of employees contributing to core business growth.
Challenges Ahead
- Expected GAAP loss of approximately ($2.10) per share for the full year 2025.
- Expected Non-GAAP loss of approximately ($0.35) per share for the full year 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...